Clinical Outcomes With a Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis: The International FORWARD Study.

Grube, Eberhard; Van Mieghem, Nicolas M; Bleiziffer, Sabine; Modine, Thomas; Bosmans, Johan; Manoharan, Ganesh; Linke, Axel; Scholtz, Werner; Tchétché, Didier; Finkelstein, Ariel; Trillo, Ramiro; Fiorina, Claudia; Walton, Antony; Malkin, Christopher J; Oh, Jae K; Qiao, Hongyan; Windecker, Stephan (2017). Clinical Outcomes With a Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis: The International FORWARD Study. Journal of the American College of Cardiology, 70(7), pp. 845-853. Elsevier 10.1016/j.jacc.2017.06.045

[img] Text
1-s2.0-S073510971737938X-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (481kB) | Request a copy

BACKGROUND Clinical outcomes in large patient populations from real-world clinical practice with a next-generation self-expanding transcatheter aortic valve are lacking. OBJECTIVES This study sought to document the clinical and device performance outcomes of transcatheter aortic valve replacement (TAVR) with a next-generation, self-expanding transcatheter heart valve (THV) system in patients with severe symptomatic aortic stenosis (AS) in routine clinical practice. METHODS The FORWARD (CoreValve Evolut R FORWARD) study is a prospective, single-arm, multinational, multicenter, observational study. An independent clinical events committee adjudicated safety endpoints based on Valve Academic Research Consortium-2 definitions. An independent echocardiographic core laboratory evaluated all echocardiograms. From January 2016 to December 2016, TAVR with the next-generation self-expanding THV was attempted in 1,038 patients with symptomatic, severe AS at 53 centers on 4 continents. RESULTS Mean age was 81.8 ± 6.2 years, 64.9% were women, the mean Society of Thoracic Surgeons Predicted Risk of Mortality was 5.5 ± 4.5%, and 33.9% of patients were deemed frail. The repositioning feature of the THV was applied in 25.8% of patients. A single valve was implanted in the proper anatomic location in 98.9% of patients. The mean aortic valve gradient was 8.5 ± 5.6 mm Hg, and moderate or severe aortic regurgitation was 1.9% at discharge. All-cause mortality was 1.9%, and disabling stroke occurred in 1.8% at 30 days. The expected-to-observed early surgical mortality ratio was 0.35. A pacemaker was implanted in 17.5% of patients. CONCLUSIONS TAVR using the next-generation THV is clinically safe and effective for treating older patients with severe AS at increased operative risk. (CoreValve Evolut R FORWARD Study [FORWARD]; NCT02592369).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0735-1097

Publisher:

Elsevier

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

12 Feb 2018 10:46

Last Modified:

09 Nov 2019 18:45

Publisher DOI:

10.1016/j.jacc.2017.06.045

PubMed ID:

28797353

Uncontrolled Keywords:

aortic stenosis degenerative valve transcatheter aortic valve replacement

BORIS DOI:

10.7892/boris.111081

URI:

https://boris.unibe.ch/id/eprint/111081

Actions (login required)

Edit item Edit item
Provide Feedback